The American Diabetes Association recommends the utilization of SGLT-2 inhibitors in stage 3 CKD patients and type 2 diabetes irrespective of glycemic control, for slowing the progression of CKD and decreasing the risk of heart failure [16]. Here, SLC5A2 is linked to chronic kidney disease.